Here, we use survival analysis to explore whether CSF biomarkers of AD-related pathology (amyloid and tau), neurodegenerative biomarkers (whole-brain and hippocampal volumes), and measures of CVD (WMH and CMB) are useful in predicting clinical progression. This evidence concerns the gene MAPT and Alzheimer disease.